pSivida Corp. (NASDAQ:PSDV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December12, 2016, pSivida Corp. (the Company) eliminated the
position of Vice President of Corporate Affairs and General
Counsel and therefore Lori Freedman, the Companys Vice President
of Corporate Affairs, General Counsel and Company Secretary, will
no longer be employed by the Company effective as of December26,
2016.
Item5.07 Submission of Matters to a Vote of Security
Holders.
The Annual Meeting of Stockholders of the Company was held on
December12, 2016. The stockholders elected each of the Companys
nominees for director, approved certain stock option and
restricted stock unit grants to the Companys President and Chief
Executive Officer, approved certain stock option grants to the
Companys non-executive directors, approved, on an advisory basis,
the Companys 2016 executive compensation, approved the Companys
2016 Incentive Plan and ratified the appointment of Deloitte
Touche LLP as the Companys independent registered public
accounting firm for fiscal year 2017. The proposals below are
described in detail in the Companys definitive proxy statement
filed with the SEC on October26, 2016.
The results are as follows:
| 1. | Election of Directors: |
| Vote type | Vote Results | |||||
|
David J. Mazzo, Ph.D. |
For | 11,535,068 | ||||
| Withheld | 5,057,549 | |||||
| NonVotes | 7,829,221 | |||||
|
Nancy Lurker |
For | 13,249,154 | ||||
| Withheld | 3,343,463 | |||||
| Non Votes | 7,829,221 | |||||
|
Michael Rogers |
For | 11,577,671 | ||||
| Withheld | 5,014,946 | |||||
| Non Votes | 7,829,221 | |||||
|
Douglas Godshall |
For | 11,576,505 | ||||
| Withheld | 5,016,112 | |||||
| Non Votes | 7,829,221 | |||||
|
James Barry, Ph.D. |
For | 11,580,505 | ||||
| Withheld | 5,012,112 | |||||
| Non Votes | 7,829,221 | |||||
|
Jay Duker, M.D. |
For | 11,949,703 | ||||
| Withheld | 4,642,914 | |||||
| Non Votes | 7,829,221 |
| 2. |
Approval of stock option and restricted stock unit grants to Nancy Lurker, President and Chief Executive Officer. |
|
Vote type |
VoteResults | |||
|
For |
12,460,546 | |||
|
Against |
3,948,469 | |||
|
Abstain |
183,602 | |||
|
NonVotes |
7,829,221 |
| 3. |
Approval of stock option grants to the following non-executive directors: |
| Votetype | VoteResults | |||||
|
David J. Mazzo, Ph.D. |
For | 10,215,707 | ||||
| Against | 6,060,957 | |||||
| Abstain | 315,953 | |||||
| NonVotes | 7,829,221 | |||||
|
Michael Rogers |
For | 10,376,196 | ||||
| Against | 6,048,169 | |||||
| Abstain | 168,252 | |||||
| Non Votes | 7,829,221 | |||||
|
Douglas Godshall |
For | 10,376,954 | ||||
| Against | 6,047,494 | |||||
| Abstain | 168,169 | |||||
| Non Votes | 7,829,221 | |||||
|
James Barry, Ph.D. |
For | 10,379,946 | ||||
| Against | 6,047,419 | |||||
| Abstain | 165,252 | |||||
| Non Votes | 7,829,221 | |||||
|
Jay Duker, M.D. |
For | 10,377,804 | ||||
| Against | 6,049,169 | |||||
| Abstain | 165,644 | |||||
| Non Votes | 7,829,221 |
| 4. |
Approval on an advisory basis of pSivida Corp.s 2016 executive compensation. |
|
Vote type |
VoteResults | |||
|
For |
10,136,615 | |||
|
Against |
6,015,860 | |||
|
Abstain |
440,142 | |||
|
Non Votes |
7,829,221 |
| 5. |
Approval of pSivida Corp. 2016 Incentive Plan |
|
Vote type |
Vote Results | |||
|
For |
11,244,595 | |||
|
Against |
5,003,191 | |||
|
Abstain |
344,831 | |||
|
Non Votes |
7,829,221 |
| 6. |
Ratification of the appointment of Deloitte Touche LLP. |
|
Vote type |
Vote Results | |||
|
For |
21,068,426 | |||
|
Against |
3,236,122 | |||
|
Abstain |
117,290 |
About pSivida Corp. (NASDAQ:PSDV)
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases. pSivida Corp. (NASDAQ:PSDV) Recent Trading Information
pSivida Corp. (NASDAQ:PSDV) closed its last trading session up +0.08 at 1.81 with 132,448 shares trading hands.
